Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Condition:   Malaria Infection Interventions:   Drug: M5717 60 mg;   Drug: Pyronaridine;   Drug: Atovaquone-Proguanil;   Drug: M5717 200 mg;   Drug: M5717 660mg Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials